Conversion of atrial fibrillation by the experimental antiarrhythmic drug tedisamil in two canine models
| Autor: | Peter S. Fischbach, Benedict R. Lucchesi, Terrance D. Barrett, James K. Hennan, Rajiva Goyal, Binh C. Tran, Zaffer A. Syed |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Drug
Hypersalivation Cyclopropanes medicine.medical_specialty Michigan Vagal stimulation media_common.quotation_subject medicine.medical_treatment Blood Pressure Cardioversion chemistry.chemical_compound Electrocardiography Dogs Heart Rate Physiology (medical) Internal medicine Atrial Fibrillation medicine Reaction Time Animals Normal Sinus Rhythm Tedisamil media_common Dose-Response Relationship Drug business.industry Models Cardiovascular Atrial fibrillation medicine.disease Bridged Bicyclo Compounds Heterocyclic Disease Models Animal chemistry Anesthesia Cardiology medicine.symptom Cardiology and Cardiovascular Medicine business Anti-Arrhythmia Agents Atrial flutter |
| Zdroj: | Journal of cardiovascular electrophysiology. 12(10) |
| ISSN: | 1045-3873 |
| Popis: | Tedisamil Conversion of AF in Two Canine Models.Introduction: Tedisamil is an experimental bradycardic agent possessing action potential-prolonging effects. It has been proven effective in terminating ventricular arrhythmias in several animal models and atrial flutter in a conscious dog model. There are no reports to date evaluating tedisamil's efficacy in terminating atrial fibrillation (AF). Methods and Results: Two different canine models of AF were used. One group of dogs (n = 6) was subjected to 28 days of chronic fibrillatory pacing at 50 Hz using an implantable neural stimulator. Sustained AF was achieved in all dogs within 14 days of initiating pacing. A second set of dogs (n = 5) had AF induced via bilateral vagal stimulation. Tedisamil 1 mg/kg was 100% effective in terminating AF in both models. Cardioversion was associated with a statistically significant prolongation of the fibrillatory cycle length immediately before return to normal sinus rhythm in both models. A dose-response trial was performed in the vagal AF group as well as in a second group of three dogs that underwent chronic fibrillatory pacing. The efficacy of tedisamil was dose dependent, with limited efficacy at 0.1 and 0.3 mg/kg intravenously in both models. Tedisamil was able to prevent reinduction of sustained AF 30 minutes after administration of 1 mg/kg in the chronic pacing model in all dogs. Side effects included minor hypersalivation in most dogs receiving the 1 mg/kg dose. No ventricular ectopy or arrhythmias were observed. Conclusion: Tedisamil is effective for conversion of sustained AF to normal sinus rhythm in two different models of AF. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text